AstraZeneca PLC
AZN1N MM
AZN1N MMAstraZeneca PLC
Mexico CompositeCompany Description
- CEO
- Mr. Pascal Soriot D.V.M., M.B.A.
- Full Time Employees
- 89,900
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge United Kingdom CB2 0AA
- Website
- www.astrazeneca.com
- Business
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Company News
AstraZeneca Shares Voting Rights Update
AstraZeneca’s New Breast Cancer Treatment Nears EU Approval
Why UK Giants Should Think Twice Before Ditching London Listing
Earnings Slew: The Bloomberg Close, Europe Edition
London Stock Exchange Boss to Join Ranks of UK’s Highest Paid Execs
AstraZeneca Sees Strong Growth in Q1 2024
AstraZeneca’s Profit Gains on Sales of Cancer Drugs
How 4% Could Be the New Inflation Target
FTSE 100 Closes at a Record for First Time in More Than a Year
FTSE 100 Closes at a Record for First Time Since February 2023
London Bankers Inch Closer to New York-Style Bumper Bonuses
Astrazeneca (AZN) Could Be a Great Choice
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
3 Pharma Stocks That Are Money-Printing Machines in 2024
The Market View on UK Stocks Is Slowly Shifting
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
EU Probe Finds No Added Suicide Risk Linked to Novo’s Wegovy
Parkinson’s Patients Must Wait for One Drug That Could Help
A CEO's Pay Raises Massive Questions for London
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know